AstraZeneca awaits decision in US Crestor patent case
This article was originally published in Scrip
Executive Summary
AstraZeneca has a lot riding on the outcome of US patent litigation relating to its cholesterol therapy, Crestor (rosuvastatin). It failed last December in its attempt to gain summary judgement on allegations of inequitable conduct in the obtainment of the active ingredient patent ('314), and as a result, Judge Joseph Farnan of the US District Court for the District of Delaware, who is overseeing the consolidated litigation, allowed arguments to continue.